Zafgen Provides Clinical Update on Beloranib Read more about Zafgen Provides Clinical Update on Beloranib Zafgen Announces Third Quarter 2015 Financial Results Read more about Zafgen Announces Third Quarter 2015 Financial Results Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results Zafgen Announces Beloranib Program Update Read more about Zafgen Announces Beloranib Program Update Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials Read more about Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials Zafgen Issues Statement Read more about Zafgen Issues Statement Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma Read more about Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma Zafgen Announces Transition of Board of Directors Read more about Zafgen Announces Transition of Board of Directors Zafgen to Present at the Leerink Rare Disease Roundtable Read more about Zafgen to Present at the Leerink Rare Disease Roundtable Zafgen to Present at Morgan Stanley Global Healthcare Conference Read more about Zafgen to Present at Morgan Stanley Global Healthcare Conference Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 … Next page Next › Last page Last » Subscribe to
Zafgen Provides Clinical Update on Beloranib Read more about Zafgen Provides Clinical Update on Beloranib
Zafgen Announces Third Quarter 2015 Financial Results Read more about Zafgen Announces Third Quarter 2015 Financial Results
Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results
Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials Read more about Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials
Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma Read more about Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma
Zafgen Announces Transition of Board of Directors Read more about Zafgen Announces Transition of Board of Directors
Zafgen to Present at the Leerink Rare Disease Roundtable Read more about Zafgen to Present at the Leerink Rare Disease Roundtable
Zafgen to Present at Morgan Stanley Global Healthcare Conference Read more about Zafgen to Present at Morgan Stanley Global Healthcare Conference